|Table of Contents|

Impact of HER2 low expression on neoadjuvant chemotherapy in breast cancer:A single-center,small-sample retrospective study

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 19
Page:
3600-3604
Research Field:
Publishing date:

Info

Title:
Impact of HER2 low expression on neoadjuvant chemotherapy in breast cancer:A single-center,small-sample retrospective study
Author(s):
WANG Wei; ZHANG Weijie; ZHUANG Xiaoming; YAO Yongzhong
Department of General Surgery, Breast Surgery,Nanjing Drum Tower Hospital,the Affiliated Hospital of Medical School,Nanjing University,Jiangsu Nanjing 210008,China.
Keywords:
breast cancer; HER2 low expression; neoadjuvant chemotherapy; therapeutic effect
PACS:
R737.9
DOI:
10.3969/j.issn.1672-4992.2023.19.012
Abstract:
Objective:To analyze clinicopathological features between breast cancer patients with HER2 low and negative expression,and to discusse the impact of HER2 low expression on the efficacy of neoadjuvant chemotherapy was discussed.Methods:The clinicopathological parameters of patients who received neoadjuvant chemotherapy in our department from January 2018 to October 2021 were collected.Patients with HER2 immunohistochemistry(IHC)1+ or 2+ butin situ hybridization(ISH) negative were included in the HER2 low expression group,and patients with IHC 0 were included in the HER2 negative group.The efficacy and prognosis of chemotherapy were compared between the two groups.Besides,the differences of HER2 expression levels before and after chemotherapy were investigated to explore the relationship between chemotherapy and HER2 heterogeneity.Results:A total of 96 patients were included in this study.Among them,39.58% were HER2 negative breast cancers and 60.42% were HER2 low expression breast cancers.There were no significant differences in age,body mass index,menstrual status,hormone receptor(HR) status,tissue grade,tumor size and axillary lymph node positive rate between the two groups.The proportion of patients with Ki-67>30% in the HER2 low expression group was smaller than that in the negative group(P=0.05).There was no significant difference in pathological complete response rate between the two groups.In the HER2 negative group,36.84% of patients had Miller & Payne score ≥4,but the proportion was only 17.24% in HER2 low expression group(P=0.03).Subgroup analysis showed that HR+ patients had worse local treatment response than HR- patients whatever in HER2 negative group or low group.Besides,HR+ patients were more likely to have an difference in DFS between the two groups.Conclusion:In this study,HER2 low expression breast cancer had lower proliferation activity,but local treatment response to neoadjuvant chemotherapy was worse than that of HER2 negative breast cancer.HR status might play a role in HER2 heterogeneous expression after chemotherapy and cause drug resistance.

References:

［1］PARAKH S,GAN HK,PARSLOW AC,et al.Evolution of anti-HER2 therapies for cancer treatment ［J］.Cancer Treat Rev,2017,59:1-21.
［2］FEHRENBACHER L,CECCHINI RS,GEYER CE,et al.NSABP B-47/NRG oncology phase Ⅲ randomized trial comparing adjuvant chemotherapy with or without trastuzumab in high-risk invasive breast cancer negative for HER2 by FISH and with IHC 1+ or 2 ［J］.J Clin Oncol,2020,38(5):444-453.
［3］ZHANG Y.The root cause of drug resistance in HER2-positive breast cancer and the therapeutic approaches to overcoming the resistance ［J］.Pharmacol Ther,2021,218:107677.
［4］OGITANI Y,AIDA T,HAGIHARA K,et al.DS-8201a,a novel HER2-targeting ADC with a novel DNA topoisomerase Ⅰ inhibitor,demonstrates a promising antitumor efficacy with differentiation from T-DM1 ［J］.Clin Cancer Res,2016,22(20):5097-5108.
［5］MODI S,PARK H,MURTHY RK,et al.Antitumor activity and safety of Trastuzumab Deruxtecan in patients with HER2-low-expressing advanced breast cancer:results from a phase Ⅰb study ［J］.J Clin Oncol,2020,38(17):1887-1896.
［6］MODI S,JACOT W,YAMASHITA T,et al.Trastuzumab Deruxtecan in previously treated HER2-low advanced breast cancer ［J］.N Engl J Med,2022,387(1):9-20.
［7］中国临床肿瘤学会乳腺癌专家委员会中国抗癌协会乳腺癌专业委员会.人表皮生长因子受体2阳性乳腺癌临床诊疗专家共识(2021版)［J］.中华医学杂志,2021,101(17):1226-1230. Chinese Anti-Cancer Association,Committee of Breast Cancer Society.2021 expert consensus on clinical diagnosis and treatment of human epidermal growth factor receptor 2 positive breast cancer ［J］.Natl Med J China,2021,101(17):1226-1230.
［8］FILHO OM,VIALE G,STEIN S,et al. Impact of HER2 heterogeneity on treatment response of early-stage HER2-positive breast cancer:phase Ⅱ neoadjuvant clinical trial of T-DM1 combined with Pertuzumab ［J］.Cancer Discov,2021,11(10):2474-2487.
［9］邵志敏,江泽飞,李俊杰,等.中国乳腺癌新辅助治疗专家共识(2019年版)［J］.中国癌症杂志,2019，29（05）：390-400. SHAO ZM,JIANG ZF,LI JJ,et al.Chinese expert consensus on neoadjuvant therapy for breast cancer(2019)［J］.China Oncology,2019,29(05):390-400.
［10］EISENHAUER EA，THERASSE P，BOGAERTS J,et al．New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)［J］.Eur J Cancer,2009,45(2):228－247.
［11］《乳腺癌新辅助治疗的病理诊断专家共识(2020版)》编写组.乳腺癌新辅助治疗的病理诊断专家共识(2020版)［J］.中华病理学杂志，2020，49(4)：296-304. Expert Consensus on Pathological Diagnosis of Neoadjuvant Therapy for Breast Cancer (2020 edition). Expert consensus on pathological diagnosis of neoadjuvant therapy for breast cancer (2020 edition)［J］.Chinese Journal of Pathology,2020,49(4):296-304.
［12］TARANTINO P,HAMILTON E,TOLANEY SM,et al.HER2-low breast cancer:pathological and clinical landscape ［J］.J Clin Oncol,2020,38(17):1951-1962.
［13］ROSSI V,SAROTTO I,MAGGIOROTTO F,et al.Moderate immunohistochemical expression of HER-2(2+)without HER-2 gene amplification is a negative prognostic factor in early breast cancer ［J］.Oncologist,2012,17(11):1418-1425.
［14］EGGEMANN H,IGNATOV T,BURGER E,et al.Moderate HER2 expression as a prognostic factor in hormone receptor positive breast cancer ［J］.Endocr Relat Cancer,2015,22(5):725-733.
［15］OCANA A,AMIR E,PANDIELLA A.HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates ［J］.Breast Cancer Res,2020,22(1):15.
［16］TARANTINO P,NICOLO E,ZAGAMI P,et al.Evolution of low HER2 expressions between primary and metastatic breast cancer ［J］.Ann Oncol,2020,31:S15-S41.
［17］DENKERT C,SEITHER F,SCHNEEWEISS A,et al.Clinical and molecular characteristics of HER2-low-positive breast cancer:pooled analysis of individual patient data from four prospective,neoadjuvant clinical trials ［J］.The Lancet Oncology,2021,22(8):1151-1161.
［18］SAATCI O,HUYNH-DAM KT,SAHIN O.Endocrine resistance in breast cancer:from molecular mechanisms to therapeutic strategies ［J］.J Mol Med(Berl),2021,99(12):1691-1710.

Memo

Memo:
江苏省自然科学基金（编号：BK20190126）
Last Update: 2023-08-31